Commission grants EUR 2.8 million to cancer camera project

A European consortium has received a EUR 2.8 million grant from the European Commission to develop a camera that can be ingested to obtain images of the digestive tract.

The three year EU funded project entitled "Nano-based capsule endoscopy with Molecular Imaging and Optical Biopsy", or "NEMO", will combine optical imaging with nanotechnologies, biosensing and manoeuvring to create an integrated imaging-biosensing system to screen for cancer of the gastrointestinal (GI) tract.

The objective of the NEMO project is to make cancer screening more patient-friendly through the development of an advanced cancer screening system.

The system will consist of a PillCam capsule endoscope capable of analysing secretions and detecting deep tissue disorders, a datarecorder on a belt that receives signals transmitted by the capsule, and a workstation enabling physicians to view and edit the video of the small intestine images.

The consortium believes that using a combination of image and molecular analysis to find the tumour could provide a new medical device for the mass screening of GI cancer.

"The project is committed to develop new and innovative solutions to help physicians treat their patients and could represent a revolutionary platform of biopsy free procedures," said Elisha Rabinovitz, the chief scientist at Given Imaging, the company leading the consortium.

The European Commission agreed to provide €2.8 million towards the total cost - slightly more than half of the total amount needed. This is because, under the rules of the Commission's Sixth Framework Programme (FP6), commercial companies can claim 50% of their costs, while academic institutions can claim up to 75%.

Meanwhile, the company behind the PillCam capsule has been heralded as one of the World Economic Forum's 2007 Technology Pioneers for its innovative camera the size of a vitamin tablet.

For more information, please visit:
http://www.givenimaging.com/Cultures/en-US/given/english

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...